A
Allyx Therapeutics
Innovative oral therapies preserving synapses for neurodegenerative disease patients
About Allyx Therapeutics
Allyx Therapeutics is a biotech startup focused on developing groundbreaking therapies to preserve and protect synapses for individuals suffering from neurodegenerative diseases. The company’s lead compound, ALX 001, is a first-in-class oral therapy that targets the mGluR5 receptor, a critical component in preventing amyloid beta-induced neuronal damage. Founded in 2019 by Yale scientists, biopharma industry veterans, and venture capitalists, Allyx Therapeutics operates in the neurodegenerative disease market, primarily serving patients and healthcare providers. The company is currently in the Series A funding stage and has successfully utilized both public and private non-dilutive funding sources, including grants from the National Institutes of Health (NIH). Allyx Therapeutics generates revenue through the development and eventual commercialization of its proprietary therapies. The company is actively engaged in clinical research, with ongoing Phase 1b trials for ALX 001, and aims to expand its pipeline to address additional neurodegenerative conditions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- New Haven, United States
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 56.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Allyx Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2025 | $27M | $106M | Bristol-Myers Squibb · Canaan Partners Israel | ↗ |
| GRANT✓Other financing | Oct 2024 | $3.3M | — | National Institutes of Health | ↗ |
Growth signals
Latest recorded traffic for Allyx Therapeutics is 1.3K monthly website visits, down 7.1% over the last three months. Allyx Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A3 investors entered at this stage
Connecticut Innovations
Bristol-Myers Squibb
Canaan Partners Israel
Other known investors5 additional known investors
Life Science Angels
Yale University
Harbor Street Ventures
Small Business Innovation Research
Yale Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Allyx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Allyx Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.